GO
Loading...

Enter multiple symbols separated by commas

Search results for "WPI"

REFINE RESULTS

SEARCH RESULTS

About 28 results. Sort By: Date | Relevance
Former Allergan CEO is still going after Pershing

Former Allergan CEO David Pyott tells a Senate hearing the SEC should investigate the Pershing Square-Valeant alliance.
Source: CNBC.com | By: Meg Tirrell
Teva's MS drug Copaxone has strong second-quarter sales

JERUSALEM, July 30- Teva Pharmaceutical Industries, which this week revealed plans to buy Allergan's generics drugs business in a $40.5 billion deal, said on Thursday sales of its branded multiple sclerosis drug Copaxone rose 12 percent in the second quarter even though it faces new competition. Teva, the world's biggest generic drug maker, said that global...
Source: Reuters
Mylan gets European clearance in proposed Perrigo takeover

NEW YORK- Mylan NV said Wednesday that it received European regulatory approval to move forward with its proposed buyout of Perrigo Co., which has resisted repeated overtures. In April, the generic drugmaker raised its offer for Perrigo to $232.23, or about $34.1 billion, in cash and stock. But Dublin- based Perrigo, which makes over-the-counter medicines, once...
Source: The Associated Press
RPT-Mylan independence from Teva's embrace comes with a price

Mylan, whose shares fell 14.5 percent, said it would continue its own unsolicited pursuit of Irish drugmaker Perrigo Co, a maker of over-the-counter consumer and nutritional products and generic topical medicines. Perrigo is one of the few remaining assets out there, "said Morningstar analyst Michael Waterhouse. Other industry analysts expect Mylan will...
Source: Reuters | By: Bill Berkrot
UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others

NEW YORK, July 27- Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger. As head of Actavis, he then sealed a $66 billion purchase of Botox-maker Allergan, beating out rival suitor Valeant...
Source: Reuters | By: Caroline Humer
US STOCKS-Wall St drops as China stock slump stokes growth fears

*Oil prices, commodities lower following China equity selloff. *Teva, Allergan jump after $40.5 bln deal. U.S.-listed shares of Chinese companies slid, including Alibaba and Baozun.
Source: Reuters | By: Noel Randewich
Teva and Restaurant Brands are big market movers

NEW YORK- Stocks that moved substantially or traded heavily Monday on the New York Stock Exchange and the Nasdaq Stock Market:. Teva Pharmaceuticals Industries Ltd., up $10.15 to $72. Restaurant Brands International Inc., up $1.41 to $41.50.
Source: The Associated Press
Analysts expect more tie-ups in generic drug business

The Dutch drugmaker Mylan, which had resisted Teva's advances for three months, is pressing ahead with its offer for Irish drug and ingredients maker Perrigo. Perrigo has turned down Mylan's offer. If they can't work it out, Perrigo might find other suitors as the competitive generic drug industry keeps consolidating.
Source: The Associated Press
US STOCKS-Wall St sinks as tumbling China equities stoke growth worry

*Oil prices, commodities lower following China equity crash. *Teva, Allergan jump after $40.5 bln deal. The NYSE showed 459 stocks at 52- week lows, the most in a day since Oct. 15.
Source: Reuters | By: Noel Randewich
US STOCKS-Wall St slumps after China stocks stumble

*Teva, Allergan jump after $40.5 bln deal. July 27- Wall Street began the week in the red on Monday and fell sharply on concerns about China's slowing growth in the wake of the biggest drop in Shanghai shares in eight years. China's top securities regulator, China Securities Regulatory Commission, said on Monday that Beijing would continue to buy shares to...
Source: Reuters | By: Tanya Agrawal